What's New

October

Proposed Rule: Possible Control of Phenethyl Bromide as a List I Chemical (PDF) (October 28, 2024)

Final Rule: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I (PDF) (October 25, 2024)

30-Day Notice: Exempt Chemical Preparations Under the Controlled Substance Act (PDF) (October 25, 2024)

David Carlos Rodriguez, M.D.; Decision and Order (PDF) (October 23, 2024)

BRX Pharmacy; Decision and Order (PDF) (October 23, 2024)

Itani Family Pharmacy, PLC; Decision And Order (PDF) (October 23, 2024)

Dale Fitzpatrick, M.D.; Decision and Order (PDF) (October 23, 2024)

Irvine Labs, Inc. (PDF) (October 23, 2024)

Mylan Technologies Inc. (PDF) (October 23, 2024)

Halo Pharmaceutical Inc. (PDF) (October 23, 2024)

Irvine Labs, Inc. (PDF) (October 23, 2024)

Final Rule: Placement of Ethylphenidate in Schedule I (PDF) (October 22, 2024)

Neeraj B. Shah, M.D.; Decision and Order (PDF) (October 21, 2024)

Michael Berman, D.O.; Decision and Order (PDF) (October 11, 2024)

William J. Mack, M.D.; Decision and Order (PDF) (October 11, 2024)

Robert P. Hansen, M.D.; Decision and Order (PDF) (October 11, 2024)

Janet S. Pettyjohn, D.O.; Decision and Order (PDF) (October 11, 2024)

Salman Akbar, M.D.; Decision and Order (PDF) (October 10, 2024)

Midtown Specialty RX; Decision and Order (PDF) (October 10, 2024)

Halowells Pharmacy; Decision and Order (PDF) (October 10, 2024)

Merry Alice Troupe, N.P.; Decision and Order (PDF) (October 8, 2024)

60-Day Notice: Application for Registration and Application for Registration Renewal; DEA Forms 224, 224A (PDF) (October 7, 2024)

Curia Wisconsin, Inc. (PDF) (October 1, 2024)

Fresenius Kabi USA, LLC (PDF) (October 1, 2024)

September

Theodore S. Wright Jr., M.D.; Decision and Order (PDF) (September 27, 2024)

Wagner Gervais, P.A.; Decision and Order (PDF) (September 27, 2024)

Lawrence Rudolph, D.M.D.; Decision and Order (PDF) (September 27, 2024)

Adam L. Larson, M.D.; Decision and Order (PDF) (September 27, 2024)

Michael Fletcher, M.D.; Decision and Order (PDF) (September 27, 2024)

Charles Sangmoah, P.A.; Decision and Order (PDF) (September 27, 2024)

Curium US LLC (PDF) (September 25, 2024)

Notice with Request for Comments: Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024 (PDF) (September 25, 2024)

Notice with Request for Comments: Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2025 (PDF) (September 25, 2024)

Proposed Amendment: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (PDF) (September 17, 2024)

George D. Gowder, III, M.D.; Decision and Order (PDF) (September 17, 2024)

Chemtos, LLC (PDF) (September 17, 2024)

Eli-Elsohly Laboratories (PDF) (September 17, 2024)

Mary A. Vreeke, M.D.; Decision and Order (PDF) (September 16, 2024)

Awesome Care Pharmacy, Inc.; Decision and Order (PDF) (September 16, 2024)

Purisys, LLC (PDF) (September 16, 2024)

Bright Green Corporation (PDF) (September 6, 2024)

Biopharmaceutical Research Company (PDF) (September 6, 2024)

Cambridge Isotope Laboratories, Inc. (PDF) (September 6, 2024)

Final Order: Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2024 (PDF) (September 5, 2024)

Samirkumar Shah, M.D.; Decision and Order (PDF) (September 4, 2024)

Chattem Chemicals (PDF) (September 4, 2024)

Bright Green Corporation (PDF) (September 4, 2024)

Continuus Pharmaceuticals (PDF) (September 4, 2024)

Catalent CTS, LLC (PDF) (September 4, 2024)

Benuvia Operations, LLC (PDF) (September 4, 2024)

Indivior Inc. (PDF) (September 4, 2024)

Amneal Complex Products Research LLC (PDF) (September 4, 2024)

Chattem Chemicals, Inc. (PDF) (September 4, 2024)

Biopharmaceutical Research Company (PDF) (September 4, 2024)

Cambridge Isotope Laboratories, Inc. (PDF) (September 4, 2024)

Fisher Clinical Services, Inc. (PDF) (September 4, 2024)

Caligor Coghlan Pharma Services (PDF) (September 4, 2024)

Cambrex High Point, Inc (PDF) (September 4, 2024)

Stephen McCarthy, P.A.; Decision and Order (PDF) (September 3, 2024)

 

  • REGISTRATION
  • REPORTING
  • RESOURCES
  • CONTACT US
  • PRIVACY NOTICE
  • GET EMAIL UPDATES